Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ford Motor Company (F) vs Novo Nordisk A/S (NVO) Price & Performance

Ford Motor CompanyTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Ford Motor Company vs Novo Nordisk A/S — how do they compare? Ford Motor Company trades at $13.98 (market cap $55.83B), while Novo Nordisk A/S trades at $47.18 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 3.7× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.29%). Which is the better fit depends on your goals.

FNVO
Market Cap
$55.83B$207.31B
Sector
Consumer CyclicalHealth
52-Week High
$17.44$63.98
52-Week Low
$11.21$35.29
Enterprise Value
$187.79B$222.02B
Dividend Yield
4.29%3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ford Motor Company

Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.

Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.

Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ford Motor Company

Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.

Read more on F

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO